Trials / Conditions / Melanoma Metastatic

Melanoma Metastatic

18 registered clinical trials studyying Melanoma Metastatic — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor NCT07442292	Peking University Cancer Hospital & Institute	—
Recruiting	A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metas NCT07076550	Alpha-9 Oncology USA Inc.	Phase 1
Recruiting	A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors NCT06889610	Fudan University	Phase 2
Recruiting	NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma NCT06889766	Centre Hospitalier Universitaire Vaudois	Phase 1
Recruiting	Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma NCT06767306	Melanoma Institute Australia	Phase 2
Recruiting	Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous NCT07050940	Azienda Ospedaliera di Perugia	N/A
Recruiting	T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma NCT06783270	Inge Marie Svane	Phase 1
Active Not Recruiting	Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable NCT06784648	BioInvent International AB	Phase 1 / Phase 2
Recruiting	Study to Evaluate Impact® as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperab NCT06880198	Fondazione Melanoma Onlus	N/A
Recruiting	Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can P NCT06784778	Pamgene International B.V.	—
Recruiting	Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC) NCT06586593	Centre Hospitalier Universitaire de Besancon	—
Active Not Recruiting	A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy NCT05732805	Biocad	Phase 3
Active Not Recruiting	Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health Sy NCT07376317	Instituto do Cancer do Estado de São Paulo	Phase 2
Unknown	Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD NCT03913923	Biocad	Phase 2
Unknown	To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compare NCT03514901	Intergruppo Melanoma Italiano	Phase 2
Terminated	Interleukin-2 in Metastatic Melanoma NCT01702896	Western Regional Medical Center	Phase 2
Terminated	Dacarbazine and Carmustine in Metastatic Melanoma NCT01692691	Western Regional Medical Center	Phase 2
Completed	Surgery for Gastrointestinal Metastases of Malignant Melanoma - a Single Center Retrospective Cohort Study NCT03879395	Vastra Gotaland Region	—